Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Positron Emission Tomography Scanning: Current and Future Applications
327
Zitationen
2
Autoren
2002
Jahr
Abstract
Whole-body positron emission tomography (PET) imaging with (18)F deoxyglucose (FDG) is a molecular imaging modality that detects metabolic alterations in tumor cells that are common to neoplastic cells. FDG-PET has recently been approved by the Health Care Finance Administration for Medicare reimbursement for diagnosing, staging, and restaging lung cancer, colorectal cancer, lymphoma, melanoma, head and neck cancer, and esophageal cancer. This review discusses the scientific evidence that led to the emergence of PET imaging as an accepted clinical tool in patients with solitary pulmonary nodules, lung cancer, colorectal cancer, melanoma, lymphoma, breast cancer, and other cancers. When possible, we compare the performance of PET to that of anatomical imaging. We discuss future clinical applications of this imaging modality.
Ähnliche Arbeiten
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 · 29.150 Zit.
Robust uncertainty principles: exact signal reconstruction from highly incomplete frequency information
2006 · 15.725 Zit.
Image processing with ImageJ
2004 · 11.903 Zit.
Fast robust automated brain extraction
2002 · 10.778 Zit.
Improved Optimization for the Robust and Accurate Linear Registration and Motion Correction of Brain Images
2002 · 10.610 Zit.